Profile
J.
Mark Braughler worked as a Director at Kylin Therapeutics, Inc. and as a Vice President-Translational Medicine at Precigen, Inc. He received his undergraduate degree from the University of Pittsburgh in 1976.
Former positions of J. Mark Braughler
Companies | Position | End |
---|---|---|
Kylin Therapeutics, Inc.
Kylin Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Kylin Therapeutics, Inc., a cutting-edge biotechnology company, employs a revolutionary RNA nanoparticle technology platform called 'pRNA' to exploit the enormous potential of RNA interference (RNAi) for treatment of many common diseases. This visionary platform has enormous potential to meet the huge market opportunity for treating cancer and other diseases with RNA-based therapeutics. The unique capabilities of the platform have enabled Kylin to overcome the most significant challenges in the development of RNA-based therapies. The formation of Kylin Therapeutics Inc., is a result of a joint partnership between IN-vivo Ventures, LLC, and Golden Pine Ventures, LLC. Together, these two companies can leverage their alliance partners and strong Board of Directors to ensure Kylin's success. A lean, cross-functional management team is set to effect early stage success. This team provides the essential ingredients to develop and promote Kylin to the next level. It is the goal of this team to provide early stage validation and market traction to attract world-class operational management with relevant credentials, track records, and operational experience. | Director/Board Member | 2013-06-30 |
PRECIGEN, INC. | Corporate Officer/Principal | - |
Training of J. Mark Braughler
University of Pittsburgh | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
PRECIGEN, INC. | Health Technology |
Private companies | 1 |
---|---|
Kylin Therapeutics, Inc.
Kylin Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Kylin Therapeutics, Inc., a cutting-edge biotechnology company, employs a revolutionary RNA nanoparticle technology platform called 'pRNA' to exploit the enormous potential of RNA interference (RNAi) for treatment of many common diseases. This visionary platform has enormous potential to meet the huge market opportunity for treating cancer and other diseases with RNA-based therapeutics. The unique capabilities of the platform have enabled Kylin to overcome the most significant challenges in the development of RNA-based therapies. The formation of Kylin Therapeutics Inc., is a result of a joint partnership between IN-vivo Ventures, LLC, and Golden Pine Ventures, LLC. Together, these two companies can leverage their alliance partners and strong Board of Directors to ensure Kylin's success. A lean, cross-functional management team is set to effect early stage success. This team provides the essential ingredients to develop and promote Kylin to the next level. It is the goal of this team to provide early stage validation and market traction to attract world-class operational management with relevant credentials, track records, and operational experience. | Commercial Services |
- Stock Market
- Insiders
- J. Mark Braughler